USFDA completes inspection at Piramal Pharma’s PPDS Ahmedabad facility

13 Jul 2024 Evaluate

United States Food and Drug Administration (USFDA) has conducted a Pre-Approval Inspection (PAI) of Piramal Pharma’s PPDS Ahmedabad facility from July 10, 2024 to July 12, 2024. The inspection was completed successfully with Zero Form - 483 observations and No Action Indicated (NAI) designation.

Successful completion of this wholistic inspection at PPDS Ahmedabad facility, will now enable access to the company's high-end analytical capabilities to its customers for their clinical and commercial batches from an FDA approved site. The company remains committed to maintain the highest standards of compliance. 

Piramal Pharma provides end-to-end pharma services to customers and a portfolio of differentiated pharma products across a domestic and global distribution network.


Piramal Pharma Share Price

252.60 -9.00 (-3.44%)
20-Dec-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1808.50
Dr. Reddys Lab 1342.45
Cipla 1472.45
Lupin 2147.55
Zydus Lifesciences 973.90
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.